Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Monopar Therapeutics as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −6 vs. Q2 2024
- Shares held
- 15.7K
- −67.9K (−81.2%) vs. Q2 2024Converted for a 1-for-5 split
- Total value
- $105.9K
- −$204.2K (−65.9%) vs. Q2 2024
- New holders
- 1
- 1 more added
- Sold out
- 7
- 1 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MNPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 95 | $576.1M |
| Q1 2026 | 82 | $341.5M |
| Q4 2025 | 74 | $360.8M |
| Q3 2025 | 56 | $354.3M |
| Q2 2025 | 43 | $113.3M |
| Q1 2025 | 35 | $109.4M |
| Q4 2024 | 18 | $57.1M |
| Q3 2024 | 6 | $105.9K |
| Q2 2024 | 12 | $310.1K |
| Q1 2024 | 16 | $268.1K |
| Q4 2023 | 14 | $91.7K |
| Q3 2023 | 14 | $182.2K |
| Q2 2023 | 8 | $164.5K |
| Q1 2023 | 11 | $322.9K |
| Q4 2022 | 10 | $471.0K |
| Q3 2022 | 10 | $314.0K |
| Q2 2022 | 13 | $470.6K |
| Q1 2022 | 13 | $519.8K |
| Q4 2021 | 13 | $657.2K |
| Q3 2021 | 9 | $964.4K |
| Q2 2021 | 10 | $1.10M |
| Q1 2021 | 13 | $1.21M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Monopar Therapeutics; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 14,066 | $94.8K | 0.00% | +2,059+17.1% | AddedConverted for a 1-for-5 split |
| GWM Advisors LLC | 600 | $4.04K | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| UBS Group AG | 512 | $3.45K | 0.00% | +512 | New |
| Wells Fargo & Company | 500 | $3.37K | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| Federation des caisses Desjardins du Quebec | 16 | $108 | 0.00% | 00.0% | UnchangedConverted for a 1-for-5 split |
| Bank of America Corp | 13 | $88 | 0.00% | −99−88.4% | ReducedConverted for a 1-for-5 split |
| Millennium Management LLC | 0 | $0 | 0.00% | −38,860−100.0% | Sold outConverted for a 1-for-5 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −9,412−100.0% | Sold outConverted for a 1-for-5 split |
| Vanguard Group Inc | 0 | $0 | 0.00% | −9,033−100.0% | Sold outConverted for a 1-for-5 split |
| Gerber, LLC | 0 | $0 | 0.00% | −5,601−100.0% | Sold outConverted for a 1-for-5 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −3,768−100.0% | Sold outConverted for a 1-for-5 split |
| Rappaport Reiches Capital Management, LLC | 0 | $0 | 0.00% | −2,139−100.0% | Sold outConverted for a 1-for-5 split |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,584−100.0% | Sold outConverted for a 1-for-5 split |